Nanoparticle Stability Patents: Who Leads, Where the Gaps Are 2026
Nanoparticle Stability and Cold Chain Patents
70.7% concentration. The top 5 of 61 ranked assignees account for 186 of 263 records in scope — filing here is dominated by a small cluster, not spread across the field. Filings rose from a single record in 2017 to a peak of 59 in 2021, then declined to 21 by 2024 — a -64% move over that three-year span. That curve tracks the mRNA vaccine cold-chain problem that dominated headlines in 2020-2021; the underlying stability science did not disappear when filing volume did, but the acute commercial pressure that drove the spike has eased.
- 1BIONTECH SE98
- 2JANSSEN PHARMA NV41
- 3PFIZER INC19
- 4BIOMATRICA INC16
- 5HDT BIO CORP12
See the full nanoparticle stability and cold chain analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents on nanoparticle stability and cold chain formulations?
One assignee leads with 98 of the 263 records in this dataset, well ahead of the rest of the field. The top five assignees combined hold 186 records, or 70.7% of all records in scope, and the top ten reach 90.9%. That means the field is concentrated among a small number of established filers rather than spread evenly across many companies, so any competitive analysis should start with those leaders’ granted claims.
Why did nanoparticle stability patent filings drop after 2021?
Filings peaked at 59 records in 2021 and fell to 21 by 2024, a 64% decline over that span. This tracks the surge in mRNA vaccine cold-chain formulation work during the pandemic, when stabilizing lipid nanoparticles for global distribution was an urgent commercial problem. The drop reflects that acute pressure easing, not the underlying stability science becoming less relevant — cryoprotectant and freeze-thaw work continues, just at lower filing volume.
What technology areas are under-claimed in nanoparticle cold-chain patents?
The medicinal-preparations class A61K covers 75.3% of the 263 records, but nanotechnology-specific claims under B82Y appear on only 8.4%, and agrochemical/biocide applications under A01N on just 10.3%. This suggests non-pharmaceutical uses of stabilized nanoparticles — agricultural delivery systems, industrial formulations — carry comparatively less prior art than the pharmaceutical core, making them worth checking before assuming a claim is blocked.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Nanoparticle Stability and Cold Chain covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.